Plitidepsin

DB04977

small molecule investigational

Deskripsi

Aplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatment for some leukemias.

Struktur Molekul 2D

Berat 1110.357
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

118 Data
Pentobarbital The metabolism of Plitidepsin can be increased when combined with Pentobarbital.
Miconazole The metabolism of Plitidepsin can be decreased when combined with Miconazole.
Tranylcypromine The metabolism of Plitidepsin can be decreased when combined with Tranylcypromine.
Letrozole The metabolism of Plitidepsin can be decreased when combined with Letrozole.
Ketoconazole The metabolism of Plitidepsin can be decreased when combined with Ketoconazole.
Amiodarone The metabolism of Plitidepsin can be decreased when combined with Amiodarone.
Metreleptin The metabolism of Plitidepsin can be increased when combined with Metreleptin.
Amphetamine The metabolism of Plitidepsin can be decreased when combined with Amphetamine.
Memantine The metabolism of Plitidepsin can be decreased when combined with Memantine.
Methimazole The metabolism of Plitidepsin can be decreased when combined with Methimazole.
Fenofibrate The metabolism of Plitidepsin can be decreased when combined with Fenofibrate.
Ethambutol The metabolism of Plitidepsin can be decreased when combined with Ethambutol.
Methoxsalen The metabolism of Plitidepsin can be decreased when combined with Methoxsalen.
Fomepizole The metabolism of Plitidepsin can be decreased when combined with Fomepizole.
Clofibrate The metabolism of Plitidepsin can be decreased when combined with Clofibrate.
Isoniazid The metabolism of Plitidepsin can be decreased when combined with Isoniazid.
Metyrapone The metabolism of Plitidepsin can be decreased when combined with Metyrapone.
Seratrodast The metabolism of Plitidepsin can be decreased when combined with Seratrodast.
Triclabendazole The metabolism of Plitidepsin can be decreased when combined with Triclabendazole.
Eletriptan The metabolism of Plitidepsin can be increased when combined with Eletriptan.
Progesterone The metabolism of Plitidepsin can be increased when combined with Progesterone.
Phenobarbital The metabolism of Plitidepsin can be increased when combined with Phenobarbital.
Prednisone The metabolism of Plitidepsin can be increased when combined with Prednisone.
Hydrocortisone The metabolism of Plitidepsin can be increased when combined with Hydrocortisone.
Prednisolone phosphate The metabolism of Plitidepsin can be increased when combined with Prednisolone phosphate.
Chlorzoxazone The metabolism of Plitidepsin can be decreased when combined with Chlorzoxazone.
Montelukast The metabolism of Plitidepsin can be decreased when combined with Montelukast.
Zidovudine The metabolism of Plitidepsin can be decreased when combined with Zidovudine.
Cinnarizine The metabolism of Plitidepsin can be decreased when combined with Cinnarizine.
Flurazepam The metabolism of Plitidepsin can be decreased when combined with Flurazepam.
Methoxyflurane The metabolism of Plitidepsin can be decreased when combined with Methoxyflurane.
Halothane The metabolism of Plitidepsin can be decreased when combined with Halothane.
Sevoflurane The metabolism of Plitidepsin can be decreased when combined with Sevoflurane.
Antipyrine The metabolism of Plitidepsin can be decreased when combined with Antipyrine.
Flunitrazepam The metabolism of Plitidepsin can be decreased when combined with Flunitrazepam.
Phenacetin The metabolism of Plitidepsin can be decreased when combined with Phenacetin.
Flunarizine The metabolism of Plitidepsin can be decreased when combined with Flunarizine.
Lorcaserin The metabolism of Plitidepsin can be decreased when combined with Lorcaserin.
Clomethiazole The metabolism of Clomethiazole can be decreased when combined with Plitidepsin.
Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Plitidepsin.
Propacetamol The metabolism of Propacetamol can be decreased when combined with Plitidepsin.
Formoterol The metabolism of Plitidepsin can be decreased when combined with Formoterol.
Arformoterol The metabolism of Plitidepsin can be decreased when combined with Arformoterol.
Tegafur-uracil The metabolism of Tegafur-uracil can be decreased when combined with Plitidepsin.
Nevirapine The metabolism of Plitidepsin can be decreased when combined with Nevirapine.
Acetaminophen The metabolism of Plitidepsin can be decreased when combined with Acetaminophen.
Clozapine The metabolism of Plitidepsin can be decreased when combined with Clozapine.
Cisapride The metabolism of Plitidepsin can be decreased when combined with Cisapride.
Metronidazole The metabolism of Plitidepsin can be decreased when combined with Metronidazole.
Nifedipine The metabolism of Plitidepsin can be decreased when combined with Nifedipine.
Ifosfamide The metabolism of Plitidepsin can be decreased when combined with Ifosfamide.
Asunaprevir The metabolism of Asunaprevir can be decreased when combined with Plitidepsin.
Cenobamate The metabolism of Cenobamate can be decreased when combined with Plitidepsin.
Azelastine The metabolism of Plitidepsin can be decreased when combined with Azelastine.
Phenytoin The metabolism of Plitidepsin can be decreased when combined with Phenytoin.
Nicotine The metabolism of Plitidepsin can be decreased when combined with Nicotine.
Selegiline The metabolism of Plitidepsin can be decreased when combined with Selegiline.
Valproic acid The metabolism of Plitidepsin can be decreased when combined with Valproic acid.
Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Plitidepsin.
Tegafur The metabolism of Tegafur can be decreased when combined with Plitidepsin.
Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Plitidepsin.
Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Plitidepsin.
Tocilizumab The metabolism of Plitidepsin can be increased when combined with Tocilizumab.
Siltuximab The metabolism of Plitidepsin can be increased when combined with Siltuximab.
Apremilast The metabolism of Plitidepsin can be increased when combined with Apremilast.
Etanercept The metabolism of Plitidepsin can be increased when combined with Etanercept.
Anakinra The metabolism of Plitidepsin can be increased when combined with Anakinra.
Adalimumab The metabolism of Plitidepsin can be increased when combined with Adalimumab.
Infliximab The metabolism of Plitidepsin can be increased when combined with Infliximab.
Abatacept The metabolism of Plitidepsin can be increased when combined with Abatacept.
Afelimomab The metabolism of Plitidepsin can be increased when combined with Afelimomab.
Canakinumab The metabolism of Plitidepsin can be increased when combined with Canakinumab.
Rilonacept The metabolism of Plitidepsin can be increased when combined with Rilonacept.
Golimumab The metabolism of Plitidepsin can be increased when combined with Golimumab.
Certolizumab pegol The metabolism of Plitidepsin can be increased when combined with Certolizumab pegol.
Secukinumab The metabolism of Plitidepsin can be increased when combined with Secukinumab.
Emapalumab The metabolism of Plitidepsin can be increased when combined with Emapalumab.
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Plitidepsin.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Plitidepsin.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Plitidepsin.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Plitidepsin.
Ropeginterferon alfa-2b The metabolism of Plitidepsin can be decreased when combined with Ropeginterferon alfa-2b.
Bimekizumab The metabolism of Plitidepsin can be increased when combined with Bimekizumab.
Lidocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Plitidepsin is combined with Phenol.

Target Protein

Palmitoyl-protein thioesterase 1 PPT1
Elongation factor 1-alpha 2 EEF1A2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 12529660
    Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M: Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia. 2003 Jan;17(1):52-9.
  • PMID: 9743292
    Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR: In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer. 1998 Sep;78(6):739-44.
  • PMID: 10410926
    Sparidans RW, Kettenes-van den Bosch JJ, van Tellingen O, Nuyen B, Henrar RE, Jimeno JM, Faircloth G, Floriano P, Rinehart KL, Beijnen JH: Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole. J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):43-53.
  • PMID: 10510788
    Celli N, Gallardo AM, Rossi C, Zucchetti M, D'Incalci M, Rotilio D: Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):335-43.
  • PMID: 10927911
    Nuijen B, Bouma M, Henrar RE, Floriano P, Jimeno JM, Talsma H, Kettenes-van den Bosch JJ, Heck AJ, Bult A, Beijnen JH: Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine. PDA J Pharm Sci Technol. 2000 May-Jun;54(3):193-208.
  • PMID: 16633717
    Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH, Schellens JH: In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
  • PMID: 31105871
    Delgado-Calle J, Kurihara N, Atkinson EG, Nelson J, Miyagawa K, Galmarini CM, Roodman GD, Bellido T: Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget. 2019 Apr 12;10(28):2709-2721. doi: 10.18632/oncotarget.26831. eCollection 2019 Apr 12.
  • PMID: 34357135
    Papapanou M, Papoutsi E, Giannakas T, Katsaounou P: Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19. J Pers Med. 2021 Jul 16;11(7). pii: jpm11070668. doi: 10.3390/jpm11070668.

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Aplidin
  • Aplidine

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul